×
About 884 results

ALLMedicine™ Acquired Hemophilia Center

Research & Reviews  425 results

Hemostatic therapy as a management strategy for acquired hemophilia: what does the futu...
https://doi.org/10.1080/17474086.2021.1892483
Expert Review of Hematology; Franchini M, Schiavulli M et. al.

Mar 3rd, 2021 - Introduction: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies that bind and inactivate factor VIII (FVIII), predisposing to a potentially life-threatening bleeding.Areas covered: The main epidemiological, clinical...

Potential Clues to the Pathogenesis of Acquired Hemophilia.
https://doi.org/10.1055/s-0040-1722294
Seminars in Thrombosis and Hemostasis; Thachil J

Mar 1st, 2021 - Potential Clues to the Pathogenesis of Acquired Hemophilia.|2021|Thachil J,|

Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concent...
https://doi.org/10.1055/s-0041-1725009
Thrombosis and Haemostasis; Takeyama M, Furukawa S et. al.

Feb 28th, 2021 - Emicizumab prophylaxis improves coagulation function in congenital hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab enhanced the coagulant potentials, ex vivo, in plasmas from patients with acquired hemophilia A...

Idiopathic Acquired Hemophilia A, a Rare Cause of Bleeding: A Case Report and Literatur...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899955
The American Journal of Case Reports; Regino CA, Alvarez JC et. al.

Feb 17th, 2021 - BACKGROUND Acquired hemophilia is a bleeding disorder mediated by an autoimmune process, in which antibodies against clotting factors are developed. This is a rarely suspected complex condition in which the initial manifestations are spontaneous b...

Acquired hemophilia A that required surgical hemostasis of hematomas occupying oral cav...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883448
Journal of Medical Case Reports; Maeda K, Yamamoto S et. al.

Feb 15th, 2021 - Acquired hemophilia A is a rare coagulopathy caused by inhibitors of blood coagulation factor VIII. Patients with acquired hemophilia A have a higher mortality risk (5-10%) than those with congenital hemophilia. Moreover, there is no established e...

see more →

Guidelines  1 results

International recommendations on the diagnosis and treatment of patients with acquired ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663620
Haematologica Huth-Kühne A, Baudo F et. al.

Apr 1st, 2009 - Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding an...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  437 results

Hemostatic therapy as a management strategy for acquired hemophilia: what does the futu...
https://doi.org/10.1080/17474086.2021.1892483
Expert Review of Hematology; Franchini M, Schiavulli M et. al.

Mar 3rd, 2021 - Introduction: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies that bind and inactivate factor VIII (FVIII), predisposing to a potentially life-threatening bleeding.Areas covered: The main epidemiological, clinical...

Potential Clues to the Pathogenesis of Acquired Hemophilia.
https://doi.org/10.1055/s-0040-1722294
Seminars in Thrombosis and Hemostasis; Thachil J

Mar 1st, 2021 - Potential Clues to the Pathogenesis of Acquired Hemophilia.|2021|Thachil J,|

Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concent...
https://doi.org/10.1055/s-0041-1725009
Thrombosis and Haemostasis; Takeyama M, Furukawa S et. al.

Feb 28th, 2021 - Emicizumab prophylaxis improves coagulation function in congenital hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab enhanced the coagulant potentials, ex vivo, in plasmas from patients with acquired hemophilia A...

Idiopathic Acquired Hemophilia A, a Rare Cause of Bleeding: A Case Report and Literatur...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899955
The American Journal of Case Reports; Regino CA, Alvarez JC et. al.

Feb 17th, 2021 - BACKGROUND Acquired hemophilia is a bleeding disorder mediated by an autoimmune process, in which antibodies against clotting factors are developed. This is a rarely suspected complex condition in which the initial manifestations are spontaneous b...

Acquired hemophilia A that required surgical hemostasis of hematomas occupying oral cav...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883448
Journal of Medical Case Reports; Maeda K, Yamamoto S et. al.

Feb 15th, 2021 - Acquired hemophilia A is a rare coagulopathy caused by inhibitors of blood coagulation factor VIII. Patients with acquired hemophilia A have a higher mortality risk (5-10%) than those with congenital hemophilia. Moreover, there is no established e...

see more →

News  19 results

New consensus recommendations on bleeding in acquired hemophilia
https://www.mdedge.com/internalmedicine/article/209872/bleeding-disorders/new-consensus-recommendations-bleeding-acquired?channel=39313
Caleb Rans

Oct 10th, 2019 - New consensus statements, released by a group of 36 experts, provide specific recommendations related to monitoring bleeding and assessing efficacy of treatment in patients with acquired hemophilia. Svisio/Thinkstock A global survey was developed.

An unusual cause of bruising
https://www.mdedge.com/ccjm/article/205517/hematology/unusual-cause-bruising/page/0/1?channel=50

Aug 1st, 2019 - FACTOR VIII INHIBITOR EVALUATION 2. What is the most likely underlying condition associated with this patient’s factor VIII inhibitor? Autoimmune disease Malignancy A medication Unknown (idiopathic) Acquired hemophilia A (AHA) is a rare disorder c.

FVIII/W ratio may help predict relapse in hemophilia A
https://www.mdedge.com/hematology-oncology/article/201468/bleeding-disorders/fviii/w-ratio-may-help-predict-relapse?channel=27970
Caleb Rans

May 22nd, 2019 - The FVIII/W (factor VIII:C/von Willebrand factor antigen) ratio appears to be a reliable biological marker to predict recovery and/or relapse in patients with acquired hemophilia A, according to a retrospective analysis. Marc Trossaert, MD, PhD, o.

FXIII replacement may improve hemostasis in acquired hemophilia A
https://www.mdedge.com/hematology-oncology/article/196298/bleeding-disorders/fxiii-replacement-may-improve-hemostasis?channel=27970
Caleb Rans

Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.

Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs
https://www.reuters.com/article/us-shire-outlook/shire-cuts-2020-revenue-target-prepares-for-spin-off-of-adhd-drugs-idUSKBN1EX1I0

Jan 8th, 2018 - LONDON (Reuters) - Shire ditched its revenue target of $20 billion by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance...

see more →